Company overview
LenioBio develops ALiCE®, a scalable eukaryotic cell-free protein expression system that produces complex proteins within 24 hours. The platform enables rapid manufacturing of vaccine-relevant proteins, antibodies, virus-like particles, and membrane proteins, reducing traditional production timelines by approximately 75%. ALiCE® supports applications from research through clinical-scale biomanufacturing, with yields up to 3mg/ml and seamless scaling from microliter to liter volumes.
Cell-Free Protein Expression Platform is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents, CDMO & Manufacturing partner serving United States & Americas. Core focus areas include cell-free protein expression, alice platform, vaccine manufacturing, protein production, biomanufacturing.
Industry categories: Life Science Reagents, CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.leniobio.com
- Categories
- Life Science Reagents, CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- cell-free protein expression, alice platform, vaccine manufacturing, protein production, biomanufacturing
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What proteins can ALiCE® produce?
- ALiCE® produces complex proteins including membrane proteins, antibodies, multispecific antibodies, virus-like particles (VLPs), vaccine-relevant antigens, and proteins requiring post-translational modifications. The system can express full-length, folded, and functional proteins.
- How fast is protein production with ALiCE®?
- ALiCE® produces proteins in 24 hours for standard applications. For vaccine development, the platform can produce vaccine-relevant proteins in 20-40 days, approximately one-quarter the time required by traditional cell culture methods.
- Does ALiCE® scale from research to manufacturing?
- Yes, ALiCE® is the only eukaryotic cell-free system designed to scale reliably from early research through large-scale production. It supports scalable expression from microliter to liter volumes, streamlining the full drug development process.
- What is the basis of LenioBio's cell-free technology?
- ALiCE® is based on a Nicotiana tabacum (tobacco) BY-2 lysate, a plant-based eukaryotic cell-free protein expression system that harnesses cellular RNA and protein synthesis machinery without living cells.
- Who are LenioBio's manufacturing partners?
- LenioBio collaborates with ReciBioPharm, a global contract development and manufacturing organization (CDMO), to scale protein manufacturing capabilities. The company also partners with Avantor for distribution across Europe.
Related editorial coverage
- Emergent BioSolutions Partners with Substipharm for $34.5M Japanese Encephalitis Vaccine Manufacturing Deal
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
